Search Results

You are looking at 1 - 9 of 9 items for :

  • sustainability x
  • History and Ethics of Medicine x
Clear All
Open access

Beti Todorovska, Nenad Joksimovic, Viktorija Caloska-Ivanova, Magdalena Dimitrova-Genadieva, Meri Trajkovska, Elena Curakova, Sanja Kiprijanovska, Beti Zafirova-Ivanovska and Vladimir Serafimoski

of metabolic factors with HCV infection:does it matter? Journal of hepatology, 2012; 56(1)S56-S65. 11. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641. 12. Grassi G, Di Caprio G, Fimia et al. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol 2016; 22(6): 1953-1965. 13. Bassendine MF, Sheridan DA, Bridge SH, et al. Lipids and HCV

Open access

Aleksandra Grozdanova, Katerina Ancevska Netkovska, Zoran Sterjev, Zorica Naumovska, Rubin Zarevski, Aleksandar Dimovski and Ljubica Suturkova

Abstract

The use of biological medicine has significantly increased in recent decades and has made substantial contributions to improving the effectiveness of therapies in many diseases. The expiration of patents of biological innovative medicines enables copies of those drugs called similar biological products (biosimilars) to be approved by regulatory authorities and to enter in clinical use. Biosimilars are comparable but not identical and are not a generic version of the innovator biological product. Although biosimilars undergo rigorous characterization as well as clinical studies to prove their safety and effectiveness, specific regulatory requirements for registration apply in the case of biosimilars. They are highly complex molecules and small changes in the production process can have major implications in its safety and effectiveness profile. The availability of biosimilars enhances competition, with the potential to improve patient access to biological medicines and to contribute to the financial sustainability of healthcare systems. In order to be certain that a biosimilar reaches its potential in clinical use, an intensive pharmacovigilance monitoring system must be established in order to prove the true similarity between the original biologic and its biosimilar. There is a need for further guidance and resolution of the ongoing discussions on biosimilar labelling, naming, pharmacovigilance and substitution in order to ensure effective and appropriate use of biosimilars in clinical practice.

Open access

Lenche Danevska, Mirko Spiroski, Doncho Donev, Nada Pop-Jordanova and Momir Polenakovic

Abstract

Introduction and aim: The Internet has enabled an easy method to search through the vast majority of publications and has improved the impact of scholarly journals. However, it can also pose threats to the quality of published articles. New publishers and journals have emerged so-called open-access potential, possible, or probable predatory publishers and journals, and so-called hijacked journals. It was our aim to increase the awareness and warn scholars, especially young researchers, how to recognize these journals and how to avoid submission of their papers to these journals.

Methods: Review and critical analysis of the relevant published literature, Internet sources and personal experience, thoughts, and observations of the authors.

Results: The web blog of Jeffrey Beall, University of Colorado, was greatly consulted. Jeffrey Beall is a Denver academic librarian who regularly maintains two lists: the first one, of potential, possible, or probable predatory publishers and the second one, of potential, possible, or probable predatory standalone journals. Aspects related to this topic presented by other authors have been discussed as well.

Conclusion: Academics should bear in mind how to differentiate between trustworthy and reliable journals and predatory ones, considering: publication ethics, peer-review process, international academic standards, indexing and abstracting, preservation in digital repositories, metrics, sustainability, etc.

Open access

Julijana Nikolovska, Dragan Petrovski, Nikola Petricevic, Biljana Kapusevska and Vesna Korunoska-Stevkovska

Abstract

Global aging population has brought several challenges for their medical systems and total edentulism is one of them. The fabrication of removable acrylic dentures seems to be a simple and cheap treatment solution, but a majority of patients is not satisfied with their functional instability, causing limited diets, mouth soreness, speech and psycho-social problems etc. The results in many studies indicate an impact of oral conditions associated with the full denture wearing on oral-health related quality of life, especially in lower jaw. The reason for improper denture retention could be alveolar ridge bone resorption and numerous studies about this problem are plausible. Bone resorption in lower jaw may turn the alveolar ridge into a flabby soft tissue which is unable to sustain proper denture retention.

The implant-retained prosthesis is an alternative treatment option in these situations. Implants will provide retention, stability, function and aesthetics and they are not so expensive solution. The aim of this article is to show solving of retention problems of a lower denture in two different clinical cases using implants and without any special technology.

Open access

Marica Pavkovic, Rosica Angelkovic, Marija Popova-Simjanovska, Sonja Genadieva-Stavric, Lidija Cevreska and Aleksandar Stojanovic

. Frequency of major molecular response to imatinib or intereferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Eng J Med. 2003; 349(15): 1423-32. 8. O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International Randomized study of Interferon versus STI571 (IRIS) 7- year follow-up: sustained survival, low rate of transformation and increase rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood. 2008

Open access

Lily Stojanovska, Bhensri Naemiratch and Vasso Apostolopoulos

in Australia: How immigrants position their difference in health care settings. Medical Anthropology 2003, 22:1-21. 17. Borovoy A, Hines J: Managing the unmanageable: elderly Russian Jewish emigrés and the biomedical culture of diabetes care. Medical Anthropology Quarter 2008, 22:1-26. 18. Pearson A, Srivastava R, Craig D, Tucker D, Grinspun D, Bajnok I, Griffin P, Long L, Porritt K, Han T et al: Systematic review on embracing cultural diversity for developing and sustaining a healthy work environment in healthcare. International

Open access

Goce Spasovski

References 1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341(23): 1725-1730. 2. Barnieh L, Yilmaz S, McLaughlin K, et al. The cost of kidney transplant over time. Prog Transplant. 2014; 24(3): 257-62. 3. James A, Mannon RB. The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? Curr Transplant Rep. 2015; 2(2): 113

Open access

Dimitar G. Efremov and Luca Laurenti

, Spijker R, de Goeij B, Jaspers A, Kater AP, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007; 109(4): 1660-8. 19. Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bom-ben R, Marasca R, et al. Intrinsic and extrinsic fac-tors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med. 2009; 7: 76. 20. Petlickovski A, Laurenti L, Li X, Marietti S, Chiu-solo P, Sica S, et al. Sustained signaling

Open access

Zorica Naumovska, Aleksandra K. Nesterovska, Ana Filipce, Zoran Sterjev, Katerina Brezovska, Aleksandar Dimovski and Ljubica Suturkova

therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol. 2007; 10(5): 631-7. 78. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006; 163(3): 529-31. 79. Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, and Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 1998; 779(1-2): 58